CDNA – CareDx, Inc
CareDx, Inc.CDNA
$22.29Name : CareDx, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $1,195,499,648.00
EPSttm : -2.69
CareDx, Inc.
$22.29
4.66%$1.09Float Short %
8.87
Margin Of Safety %
-17
Put/Call OI Ratio
0.48
EPS Next Q Diff
-0.05
EPS Last/This Y
EPS This/Next Y
0.15
Price
22.28
Target Price
32.38
Analyst Recom
1.89
Performance Q
3.39
Relative Volume
1.11
Beta
1.95
Ticker: CDNA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | CDNA | 23.35 | 0.33 | 0.01 | 1321 |
| 2025-01-24 | CDNA | 22.35 | 0.27 | 0.26 | 1575 |
| 2025-01-27 | CDNA | 22.59 | 0.27 | 0.00 | 1594 |
| 2025-01-28 | CDNA | 22.84 | 0.26 | 0.00 | 1605 |
| 2025-01-29 | CDNA | 22.54 | 0.26 | 2.33 | 1609 |
| 2025-01-30 | CDNA | 23 | 0.28 | 5.00 | 1639 |
| 2025-01-31 | CDNA | 23.29 | 0.28 | 0.00 | 1643 |
| 2025-02-03 | CDNA | 23.38 | 0.28 | 0.00 | 1646 |
| 2025-02-04 | CDNA | 23.09 | 0.28 | 0.06 | 1650 |
| 2025-02-05 | CDNA | 23.57 | 0.28 | 0.00 | 1643 |
| 2025-02-06 | CDNA | 22.71 | 0.26 | 0.14 | 1793 |
| 2025-02-07 | CDNA | 22.37 | 0.25 | 0.07 | 1803 |
| 2025-02-10 | CDNA | 24.89 | 0.25 | 0.19 | 1809 |
| 2025-02-11 | CDNA | 22.97 | 0.28 | 2.16 | 3211 |
| 2025-02-12 | CDNA | 23.72 | 0.46 | 0.05 | 3868 |
| 2025-02-13 | CDNA | 24.82 | 0.45 | 0.08 | 3969 |
| 2025-02-14 | CDNA | 24.51 | 0.44 | 0.37 | 4017 |
| 2025-02-18 | CDNA | 24.47 | 0.45 | 1.54 | 4133 |
| 2025-02-19 | CDNA | 24.7 | 0.47 | 0.55 | 4169 |
| 2025-02-20 | CDNA | 23.34 | 0.47 | 0.38 | 4246 |
| 2025-02-21 | CDNA | 22.29 | 0.48 | 1.53 | 4292 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | CDNA | 23.43 | 170.6 | - | 0.42 |
| 2025-01-24 | CDNA | 22.35 | 170.6 | - | 0.42 |
| 2025-01-27 | CDNA | 22.57 | 170.6 | - | 0.42 |
| 2025-01-28 | CDNA | 22.84 | 170.6 | - | 0.42 |
| 2025-01-29 | CDNA | 22.56 | 170.6 | - | 0.42 |
| 2025-01-30 | CDNA | 22.98 | 186.8 | - | 0.42 |
| 2025-01-31 | CDNA | 23.23 | 186.8 | - | 0.42 |
| 2025-02-03 | CDNA | 23.32 | 186.8 | - | 0.42 |
| 2025-02-04 | CDNA | 23.10 | 186.8 | - | 0.42 |
| 2025-02-05 | CDNA | 23.57 | 186.8 | - | 0.42 |
| 2025-02-06 | CDNA | 22.71 | 186.8 | - | 0.42 |
| 2025-02-07 | CDNA | 22.38 | 186.8 | - | 0.42 |
| 2025-02-10 | CDNA | 24.91 | 186.8 | - | 0.42 |
| 2025-02-11 | CDNA | 22.83 | 186.8 | - | 0.42 |
| 2025-02-12 | CDNA | 23.96 | 186.8 | - | 0.42 |
| 2025-02-13 | CDNA | 24.82 | 186.8 | - | 0.42 |
| 2025-02-14 | CDNA | 24.50 | 186.8 | - | 0.42 |
| 2025-02-18 | CDNA | 24.49 | 186.8 | - | 0.42 |
| 2025-02-19 | CDNA | 24.70 | 186.8 | - | 0.42 |
| 2025-02-20 | CDNA | 23.40 | 186.8 | - | 0.42 |
| 2025-02-21 | CDNA | 22.28 | 186.8 | - | 0.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | CDNA | -4.06 | -1.94 | 7.90 |
| 2025-01-24 | CDNA | -4.06 | -1.94 | 7.90 |
| 2025-01-27 | CDNA | -4.06 | -1.88 | 7.90 |
| 2025-01-28 | CDNA | -4.06 | -1.88 | 8.74 |
| 2025-01-29 | CDNA | -4.06 | -1.88 | 8.74 |
| 2025-01-30 | CDNA | -4.06 | -1.88 | 8.74 |
| 2025-01-31 | CDNA | -4.06 | -1.88 | 8.74 |
| 2025-02-03 | CDNA | -4.06 | 3.57 | 8.74 |
| 2025-02-04 | CDNA | -4.06 | 3.57 | 8.74 |
| 2025-02-05 | CDNA | -4.06 | 3.57 | 8.74 |
| 2025-02-06 | CDNA | -4.16 | 3.57 | 8.74 |
| 2025-02-07 | CDNA | -4.16 | 3.57 | 8.74 |
| 2025-02-10 | CDNA | -4.16 | 8.67 | 8.77 |
| 2025-02-11 | CDNA | -3.98 | 8.67 | 8.77 |
| 2025-02-12 | CDNA | -3.98 | 8.67 | 8.90 |
| 2025-02-13 | CDNA | -3.98 | 8.67 | 8.90 |
| 2025-02-14 | CDNA | -4.13 | 8.67 | 8.87 |
| 2025-02-18 | CDNA | -4.13 | 4.38 | 8.87 |
| 2025-02-19 | CDNA | -4.17 | 4.38 | 8.87 |
| 2025-02-20 | CDNA | -4.17 | 4.38 | 8.87 |
| 2025-02-21 | CDNA | -4.17 | 4.38 | 8.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.14
Avg. EPS Est. Current Quarter
0.05
Avg. EPS Est. Next Quarter
0.09
Insider Transactions
-4.17
Institutional Transactions
4.38
Beta
1.95
Average Sales Estimate Current Quarter
82
Average Sales Estimate Next Quarter
85
Fair Value
18.48
Quality Score
34
Growth Score
51
Sentiment Score
61
Actual DrawDown %
77.7
Max Drawdown 5-Year %
-94.9
Target Price
32.38
P/E
Forward P/E
PEG
P/S
3.82
P/B
4.33
P/Free Cash Flow
979.92
EPS
-2.7
Average EPS Est. Cur. Y
0.42
EPS Next Y. (Est.)
0.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-45.9
Relative Volume
1.11
Return on Equity vs Sector %
-71.8
Return on Equity vs Industry %
-63.1
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.17
EBIT Estimation
CareDx, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 635
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
stock quote shares CDNA – CareDx, Inc Stock Price stock today
news today CDNA – CareDx, Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CDNA – CareDx, Inc yahoo finance google finance
stock history CDNA – CareDx, Inc invest stock market
stock prices CDNA premarket after hours
ticker CDNA fair value insiders trading